Cell Res: Fudan University has released a three-negative breast cancer treatment plan that allows patients to go from mountains to mountains.

According to !---- the 2018 International Agency for Research on Cancer (IARC), breast cancer has a global incidence of 24.2 percent of female cancers, the highest rate among women, with 52.9 percent of them in developing countries.from the age of onset, the incidence of breast cancer from the age of 20 began to gradually increase, 45 to 50 years of age peak.in China, the incidence of breast cancer is on the rise year by year, more than 300,000 women are diagnosed with breast cancer every year, in the eastern coastal areas and economically developed cities, the incidence of breast cancer is particularly obvious.triple-negative breast cancer (TNBC) is one of all breast cancers, known as "triple negative" due to estrogen receptors, progesterone receptors and HER-2, which are all negative targets for treatment, accounting for about 15 percent of all breast cancers.this type of breast cancer is considered the "most toxic and dangerous" breast cancer due to lack of targets and high risk of recurrence and metastasis., because after many rounds of treatment, the disease is still progressing three negative breast cancer is close to "mountain exhaustion", after conventional treatment of the tumor reduction of less than 10% of patients. On 27 July, the team of The Mamtoma Surgery Director of Fudan University Affiliated Oncology Hospital, Professor Zhai Zhimin, published a research paper entitled "Molecular Subtyping and Genomic pro-life-field field ingosine inory metastatic triple-negative cancer: the future trial".the study provides a "precision treatment plan" for "three-negative breast cancer that is still progressing after multiple rounds of treatment": combined with the "gene map" of this type of late refractory triple-negative breast cancer and the detection data of more than 500 gene hotspots, precision treatment is carried out according to the "Fudan type" invented earlier, and the proportion of patients with tumor reduction after treatment has been successfully increased from less than 10% to 29%, and some of the patients with sub-triple-negative breast cancer have been extended to a far greater extent. How doeshope for triple-negative breast cancer patients who are still progressing after multiple rounds of treatment? A five-year study by Professor Zhai Zhimin's team, in 2019, mapped the world's largest genetic map of triple-negative breast cancer, confirming that triple-negative breast cancer is not a single type of disease, but is actually a hybrid collective, and in-depth study is expected to further subdivide the group.strengthen research through gene sequence and expression, or solve the problem of "no target" of triple-negative breast cancer.through a huge genetic data analysis, the research team based on different genetic characteristics, the first international "Fudan type" standard, and based on the three-negative breast cancer into four different subtypes: immunomodulation type, cavity androgen body type, substrate-based immunosuppressive type, interstitial type. "A lot of sequencing in the laboratory provides us with a wealth of genetic data, but clinically it is necessary to make it easier and faster to identify the classification of triple-negative breast cancer, so as to guide accurate treatment, and after a series of computational analyses, we have set up four clinically commonly used immune cluster markers (androgen receptors, CD8, FOXC1, DCLK1) as a 'label' for triple-negative breast cancer subtypes," said Professor Zhai Zhimin of.clinically only need to test these four 'labels' to quickly arrive at typed results."After a large number of experimental verification, through the results of 4 "label" tests and patients' genetic test results are highly consistent, to ensure the accuracy of the test.and fortunately, this method of finding "labels" requires only hundreds of dollars in immuno-grouped testing, a short diagnosis that takes short time and has a wide range of promotionability.targeted: greatly improve the "hardest to treat" breast cancer mitigation rate further analysis found that different triple-negative breast cancer cells showed a large difference in characteristics, to immunomodulated three-negative breast cancer for example, compared to other subtypes, such breast cancer cells around a large number of lymphocytes, which means that such subtypes may be sensitive to immunotherapy; This type of patient may be suitable for targeted targeted treatment..." Based on a precise typesetting approach, Professor Zhai Zhimin of Breast Surgery of the Cancer Hospital and Professor Wang China conducted an "umbrella" study called "FUTURE" to perform "the most difficult treatment" of triple-negative breast cancer after multiple rounds of treatment, to perform type-setting and genetic testing, and to guide the follow-up corresponding precision treatment.study included 69 patients with "the most difficult" triple-negative breast cancer with almost no cure. combined with previous classification "tags" to classify these patients, the team tested more than 500 hot-spot genes, accurately targeting the characteristics of cancer cells in different categories of patients, and then targeted therapy accordingly. "We are pleased to find that about 29% of these patients who are almost 'mountain-poor' have been given 'willow sly blooms' and the tumor has shrunk significantly, " said Professor Zhai Zhimin, . Far more than the current international cutting-edge treatment of about 10% of the mitigation rate, of which, more exciting is those classified as 'immune-regulated' patients with refractory triple-negative breast cancer, through immunotherapy and combined chemotherapy methods, 52.6% of the tumor smaller, the disease is well controlled. the team found that although THE HER2 test was negative, there was a mutation in the HER2 gene in three negative breast cancer patients classified as "cavity androgen subject type". team tried to target the treatment against HER2 in this part of the patient who had the mutation. found that the proportion of tumors in these patients decreased by as much as 100%. one of the patients has been in remission for more than six months. is unique, in the same period published in the FUTURE study, the world's leading academic journal Nature also published the results of the study of precision treatment of lung cancer umbrella research, also confirmed the clinical value of classified precision treatment in refractive cancer. expanded: Fudan classification is expected to expand further in the FUTURE study, the research team continues to find that "new continent", such as the classification of "cavity androgen receptor type" of triple-negative breast cancer is higher than expected malignant, faster progress, and the treatment of androgen receptors is insensitive. this part of the patient needs to further analyze its characteristics, and adjust the corresponding treatment plan for long-term efficacy..." These 'unexpected' results provide ideas for future research on three-negative breast cancer, further confirm that the promotion of 'Fudan type' and accurate detection in advanced triple-negative breast cancer is very necessary, but also provides data and evidence for the follow-up clinical trials of three-negative breast cancer, " said Prof. for example, in future research, oncology hospital breast surgery and one of the most powerful domestic drug research and development enterprises Hengrui company close cooperation, the two sides will be cutting-edge drugs and research targets one-to-one correspondence, in the cooperation issued a lot of inspiration, making it a first-class cancer medical center and excellent pharmaceutical companies to cooperate with the model. more research results engraved with "Fudan Tumor" and representing the highest level of breast cancer in China have gone from Shanghai to the world. for three negative breast cancer heavy original scientific research results launched in succession, not only become Fudan University affiliated cancer hospital three negative breast cancer research source of the "high-gloss moment", but also lit up the patient's "light of life." .